产品说明书
BMS-3
 |
同义名 : | - |
| CAS号 : | 1338247-30-5 | |
| 货号 : | A343340 | |
| 分子式 : | C17H12Cl2F2N4OS | |
| 纯度 : | 99%+ | |
| 分子量 : | 429.271 | |
| MDL号 : | MFCD17019326 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(244.6 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | LIMK1 and LIMK2 regulate the actin cytoskeleton by phosphorylating and inactivating the cofilin family of actin-depolymerizing factors; LIMK1 also acts to destabilize microtubules and regulates cell motility, including tumor metastasis. The initial lead compound BMS-3 is a potent inhibitor of both LIMK activity and tubulin polymerization. In A549 cells, BMS-3 caused a dose-dependent reduction in cell count and induced mitotic arrest as shown by increases in total nuclear DNA intensity and histone H3 phosphorylation after 24 h treatment. The Affymetrix array contains probesets for 17 tubulin subunits; a dose-related decrease in signal for up to eight of these was seen with the treatment of BMS-3 suggesting it reduced the levels of tubulin transcripts. Relative to the vehicle control, addition of 10 μmol/L BMS-3 also decreased the rate and level of microtubule polymerization [2]. Inhibition of LIMK1 by BMS-3 resulted in lower levels of actin polymerization during capacitation and a dramatic decrease in the percentage of sperm that undergo acrosomal exocytosis [1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.33mL 0.47mL 0.23mL |
11.65mL 2.33mL 1.16mL |
23.30mL 4.66mL 2.33mL |
| 参考文献 |
|---|